News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ACC 2025 STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients L.A. McKeown March 29, 2025
News Conference News ACC 2024 Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC Michael O'Riordan April 08, 2024
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2020 New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy L.A. McKeown April 02, 2020
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Conference News ACC 2018 ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More Shelley Wood March 12, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018